Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation

Both the anterior juxtascleral depot of a drug and anecortave acetate may be promising candidates for IOP reduction in eyes with OAG. Additional studies are required to establish better their efficacy and safety, optimal dosing frequency, mechanism of action, and potential additivity to other IOP-lowering therapies.